The specter of generic rivalry has long loomed above copyright’s famous drug, Sildenafil, triggering questions about the outlook of similar pharmaceutical holdings. While first years saw substantial gains, the intellectual property expiration has opened the door for less expensive substitutes, likely diminishing profitability and posing a genuine